SCHEMBL6682849

SCHEMBL6682849

COc1cc(C(F)(F)F)ccc1S(=O)(=O)Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 2/20 0.60
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
ALPL P05186 2/20 0.43
KIF11 P52732 1/20 0.43
SCN9A Q15858 3/20 0.41
GAA P10253 1/20 0.41
NAMPT P43490 1/20 0.40
NR1I2 O75469 1/20 0.39
AVPR2 P30518 1/20 0.39
GPR27 Q9NS67 1/20 0.39
CYP2C19 P33261 3/20 0.39
MAPT P10636 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
HTR2A P28223 1/20 0.39
KDM4E B2RXH2 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31494541 1.00 TRPV4 (0.60) TRPV4MEN1KMT2AALOX15MAPK1
SCHEMBL5348639 0.87 TRPV4 (0.57) TRPV4MEN1KMT2AALOX15MAPK1
SCHEMBL1036692 0.87 ALPL (0.52) TRPV4MEN1KMT2AALOX15MAPK1
SCHEMBL30440381 0.86 TRPV4 (0.64) TRPV4MEN1KMT2AALPLGAA
SCHEMBL2747879 0.86 TRPV4 (0.64) TRPV4MEN1KMT2AALPLGAA
SCHEMBL25318109 0.83 KMT2A (0.43) TRPV4MEN1KMT2AALOX15MAPK1
SCHEMBL8764653 0.83 TRPV4 (0.57) TRPV4MAPK1SCN9ACYP2C19MAPT
SCHEMBL25362679 0.79 MCL1 (0.51) TRPV4MEN1KMT2AMAPK1KIF11
SCHEMBL4676395 0.78 TRPV4 (0.54) TRPV4GAAMAPTKDM4EALDH1A1
SCHEMBL2502219 0.78 TRPV4 (0.57) TRPV4ALPLKIF11GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4448109-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS Aurigene Oncology Limited (IN) 2024-10-23 EP disclosed
WO-2023114710-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-06-22 WO disclosed
WO-2023114710-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-06-22 WO disclosed
EP-1290001-B1 PROCESS FOR THE SELECTIVE DEPROTONATION AND FUNCTIONALIZATION OF 3-SUBSTITUTED BENZOTRIFLUORIDES DOW AGROSCIENCES LLC (US) 2004-11-03 EP disclosed
EP-1290001-A1 PROCESS FOR THE SELECTIVE DEPROTONATION AND FUNCTIONALIZATION OF 3-SUBSTITUTED BENZOTRIFLUORIDES Dow AgroSciences LLC (US) 2003-03-12 EP disclosed
US-6462240-B2 FROMING 2-LITHIOBENZOTRIFLORIDE FROM BENZOTRIFLUORIDE AND ALKYLLITHIUM DOW AGROSCIENCES LLC 2002-10-08 US disclosed
US-20020010375-A1 Process for the selective deprotonation and functionalization of 3-substituted benzotrifluorides CORTEVA AGRISCIENCE LLC 2002-01-24 US disclosed
WO-2001096348-A1 PROCESS FOR THE SELECTIVE DEPROTONATION AND FUNCTIONALIZATION OF 3-SUBSTITUTED BENZOTRIFLUORIDES DOW AGROSCIENCES LLC (US) 2001-12-20 WO disclosed
EP-0511826-B1 Phosphosulfonate herbicides ROHM & HAAS (US) 1997-07-16 EP disclosed
US-5500405-A Phosphosulfonate herbicides ROHM AND HAAS COMPANY (US) 1996-03-19 US disclosed
US-5272128-A Phosphosulfonate herbicides ROHM AND HAAS COMPANY (US) 1993-12-21 US disclosed
EP-0511826-A2 Phosphosulfonate herbicides ROHM AND HAAS COMPANY (US) 1992-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010375-A1 Process for the selective deprotonation and functionalization of 3-substituted benzotrifluorides BPTF, FGFR2, FGFR4 TRPV4 209/4885MEN1 2913/4885KMT2A 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.